Literature DB >> 34392752

Inverse optimal control to model human trajectories during locomotion.

Isabelle Maroger1, Olivier Stasse1, Bruno Watier1.   

Abstract

Cobotic applications require a good knowledge of human behaviour in order to be cleverly, securely and fluidly performed. For example, to make a human and a humanoid robot perform a co-navigation or a co-manipulation task, a model of human walking trajectories is essential to make the robot follow or even anticipate the human movements. This paper aims to study the Center of Mass (CoM) path during locomotion and generate human-like trajectories with an optimal control scheme. It also proposes a metric which allows to assess this model compared to the human behaviour. CoM trajectories during locomotion of 10 healthy subjects were recorded and analysed as part of this study. Inverse optimal control was used to find the optimal cost function which best fits the model to the measurements. Then, the measurements and the generated data were compared in order to assess the performance of the presented model. Even if the experiments show a great variability in human behaviours, the model presented in this study gives an accurate approximation of the average human walking trajectories. Furthermore, this model gives an approximation of human locomotion good enough to improve cobotic tasks allowing a humanoid robot to anticipate the human behaviour.

Entities:  

Keywords:  Locomotion analysis; human-robot interaction; model-based simulation; modeling; optimal control

Mesh:

Year:  2021        PMID: 34392752     DOI: 10.1080/10255842.2021.1962311

Source DB:  PubMed          Journal:  Comput Methods Biomech Biomed Engin        ISSN: 1025-5842            Impact factor:   1.763


  1 in total

1.  Walking paths during collaborative carriages do not follow the simple rules observed in the locomotion of single walking subjects.

Authors:  Isabelle Maroger; Manon Silva; Hélène Pillet; Nicolas Turpin; Olivier Stasse; Bruno Watier
Journal:  Sci Rep       Date:  2022-09-16       Impact factor: 4.996

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.